Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors

Core Insights - Kyverna Therapeutics has appointed Mert Aktar as an independent director to its Board of Directors, enhancing the board's expertise in corporate strategy and business development, particularly in biopharmaceuticals and cell therapy [1][2] Company Overview - Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases [3][4] - The company is advancing its lead CAR T-cell therapy candidate, KYV-101, through clinical trials targeting autoimmune diseases such as stiff-person syndrome, multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis [4] Leadership and Expertise - Mert Aktar brings over two decades of biopharmaceutical experience, including significant roles in corporate development and strategy at Kite Pharma and Shire, where he facilitated multi-billion-dollar transactions [2][3] - His appointment is expected to provide strategic guidance and operational leadership as Kyverna progresses with KYV-101 and aims to expand its market presence [2][3] Clinical Development - KYV-101 is currently in various stages of clinical trials, including Phase 2 trials for multiple autoimmune conditions and ongoing Phase 1/2 trials in the U.S. and Germany [4] - The pipeline includes next-generation CAR T-cell therapies designed for B cell-driven autoimmune diseases, indicating a focus on innovative treatment modalities [4]